Abstract 1505TiP
Background
Immunotherapy has improved survival in patients (pts) with adv/met NSCLC. However, outcomes remain poor in pts with PD-L1 expression <50%, and more efficacious treatments are needed. Dato-DXd is an antibody-drug conjugate composed of a TROP2 directed monoclonal antibody covalently linked to a highly potent cytotoxic payload via a stable, tumor-selective, tetrapeptide-based cleavable linker. In the phase 1b TROPION-Lung02 trial, Dato-DXd + pembro ± Pt-CT had tolerable safety and promising antitumor activity in pts with adv/met NSCLC, notably as 1L therapy and irrespective of PD-L1 levels. Here, we describe the TROPION-Lung07 trial of Dato-DXd + pembro ± Pt-CT in pts with adv/met NSCLC without actionable genomic alterations (AGA) and PD-L1 expression <50%.
Trial design
TROPION-Lung07 (NCT05555732) is a global, randomized, open-label, phase 3 trial of 1L Dato-DXd + pembro ± Pt-CT in pts with nonsquamous adv/met NSCLC without AGA with PD-L1 expression <50%. Dato-DXd + pembro ± Pt-CT will be compared with pemetrexed + pembro + Pt-CT. Approximately 975 pts will be randomized 1:1:1 to Dato-DXd 6 mg/kg + pembro 200 mg (max, 35 cycles) ± Pt-CT (cisplatin 75 mg/m2 or carboplatin area under the curve 5; max, 4 cycles) every 3 weeks (Q3W) or pemetrexed 500 mg/m2 + pembro 200 mg + Pt-CT Q3W. Pts will be stratified by PD-L1 levels, Eastern Cooperative Oncology Group performance status, geographic region, and investigator choice of Pt-CT. Pts must have stage IIIB/C NSCLC ineligible for resection or definitive chemoradiation or stage IV disease and must not have received prior systemic therapy for adv/met NSCLC. The primary endpoints are progression-free survival by blinded independent central review and overall survival. Secondary endpoints include objective response rate (ORR), duration of response, time to response, disease control rate, and safety. Pt-reported outcomes, pharmacokinetics, and biomarkers will be explored. Enrollment is currently ongoing in the United States, Australia, China, Japan, Republic of Korea, Taiwan, and Thailand.
Clinical trial identification
NCT05555732.
Editorial acknowledgement
Medical writing support was provided by Martin Haschak, PhD, of SciMentum, Inc, a Nucleus Holdings Ltd company, and was funded by Daiichi Sankyo, Inc. Editorial support was provided in accordance with good publication practice guidelines (ismpp.org/gpp-2022).
Legal entity responsible for the study
Daiichi Sankyo, Inc.
Funding
Daiichi Sankyo, Inc.
Disclosure
I. Okamoto: Financial Interests, Personal, Speaker, Consultant, Advisor: Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd, AstraZeneca, Eli Lilly Japan K.K., Takeda Pharmaceutical Company Limited, Novartis Pharma K.K.; Financial Interests, Institutional, Research Funding: Daiichi Sankyo, Chugai Pharma, Lilly, Bristol Myers Squibb, MSD Oncology, AstraZeneca, Taiho Pharmaceutical, Boehringer Ingelheim, Ono Pharmaceutical. S. Kuyama: Financial Interests, Other, Honoraria: AstraZeneca K.K., Bristol Myers Squibb Company, Hisamitsu Pharmaceutical Co.,Inc., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Pfizer Japan Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited., Kyowa Kirin Co., Ltd.. N. Girard: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD, Roche, Pfizer, Mirati, Amgen, Novartis, Sanofi, Gilead; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Roche, Pfizer, Janssen, Boehringer, Novartis, Sanofi, AbbVie, Amgen, Lilly, Grunenthal, Takeda, Owkin, Leo Pharma, Daiichi Sankyo, Ipsen; Financial Interests, Institutional, Research Grant, Local: Roche, Sivan, Janssen; Financial Interests, Institutional, Funding: BMS, Leo Pharma; Financial Interests, Institutional, Research Grant: MSD; Non-Financial Interests, Officer, International Thymic malignancy interest group, president: ITMIG; Other, Family member is an employee: AstraZeneca. S. Lu: Financial Interests, Other, Grants or contracts: AstraZeneca, Hutchison, BMS, Heng Rui, BeiGene, Roche, Hansoh; Financial Interests, Other, Consulting fees: AstraZeneca, Pfizer , Boehringer Ingelheim, Hutchison, MediPharma, Simcere, ZaiLab, GenomiCare , Yuhan Corporation, PrIME Oncology, Menarini, InventisBio Co. Ltd., Roche; Financial Interests, Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AstraZeneca, Roche, Hansoh, Hengrui Therapeutics; Financial Interests, Other, Participation on a Data Safety Monitoring Board or Advisory Board: Roche, Regenron, AstraZeneca, Simcere Zaiming Pharmaceutical Co., Ltd; Financial Interests, Other, Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Chinese Lung Cancer Associate, CSCO. F.A. Franke: Financial Interests, Personal, Speaker, Consultant, Advisor: Novartis, BMS, MSD, Daiichi Sankyo; Financial Interests, Institutional, Principal Investigator: Daiichi Sankyo, Lilly, Bristol Myers Squibb, MSD Oncology, AstraZeneca, Takeda, Roche, Amgen, Pfizer, Novartis, Gilead, Merck. N. Ren: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo; Financial Interests, Personal, Stocks or ownership: Daiichi Sankyo; Financial Interests, Personal, Other, Travel, accommodations, expenses: Daiichi Sankyo. E. Oputa: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo; Financial Interests, Personal, Stocks or ownership: PPD, Syneos Health. A.E. Lisberg: Financial Interests, Personal, Full or part-time Employment, Immediate Family Member: Boston Scientific; Financial Interests, Personal, Stocks or ownership, Immediate Family Member: Boston Scientific; Financial Interests, Personal, Other, Consulting or advisory role: AstraZeneca, Bristol Myers Squibb, Leica Biosystems, Jazz Pharmaceuticals , Novocure, Pfizer, MorphoSys , Eli Lilly, Oncocyte, Novartis, Regeneron, Janssen Oncology, Sanofi group of companies; Financial Interests, Institutional, Research Funding: Daiichi Sankyo, Calithera Biosciences, AstraZeneca, Dracen Pharmaceuticals, WindMIL, eFFECTOR Therapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
1543P - Clinical study of camrelizumab combined with docetaxel and carboplatin in neoadjuvant treatment of locally advanced oesophageal squamous cell carcinoma
Presenter: Rui Wang
Session: Poster session 21
1544P - Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment of advanced gastric/gastroesophageal junction cancer: A phase II clinical trial
Presenter: Xin fang Hou
Session: Poster session 21
1545P - Phase II trial of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus
Presenter: Yuexiao Qi
Session: Poster session 21
1546P - Safety, efficacy, and biomarkers for ONO-4578 plus nivolumab in unresectable advanced or recurrent gastric or gastroesophageal cancer
Presenter: Hidekazu Hirano
Session: Poster session 21
1547P - SNP discovery based on transcriptome sequencing of whole blood RNA to find predictive biomarkers for nivolumab in gastric cancer
Presenter: Chiaki Inagaki
Session: Poster session 21
1549P - A prospective study of circulating tumor DNA (ctDNA) genomic profiling in gastric or gastroesophageal junction (GEJ) cancer patients with recurrence after adjuvant chemotherapy: Liquid-GEAR trial
Presenter: Hiroyuki Takeda
Session: Poster session 21
1551P - Clinicopathologic characteristics and genomic profiling of HER2-low advanced gastric cancer
Presenter: Choong-kun Lee
Session: Poster session 21
1552P - Clinical multi-omics analysis of gastric cancer (GC) in Europe (EU) and Latin America (LatAm): The LEGACy project
Presenter: Tania Fleitas
Session: Poster session 21
1553P - Blood-borne assessment of stromal activation in esophageal adenocarcinoma to guide tocilizumab therapy: A randomized phase II proof-of-concept study
Presenter: Benthe Doeve
Session: Poster session 21